Breast Cancer (ASCO) Basic Listing

Updates in Breast Cancer

From the ASCO Annual Meeting

Conference Coverage

Sacituzumab Tirumotecan Improves Survival Outcomes Among Patients With Advanced Triple-Negative Breast Cancer

05/28/2024

According to phase 3 data to be presented at the 2024 ASCO Annual Meeting, sacituzumab tirumotecan improved progression-free survival and overall survival compared to chemotherapy with manageable safety for heavily pre-treated patients with...

According to phase 3 data to be...

05/28/2024

Oncology

Javier Cortes, MD, PhD, International Breast Cancer Center, Madrid, Spain

Videos

Chemotherapy De-escalation for HER2-Positive Early Breast Cancer

06/21/2023

Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.

Javier Cortes, MD, PhD,...

06/21/2023

Oncology

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute

Videos

Sacituzumab Govetican Improves Survival Outcomes For Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/08/2023

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

Sara Tolaney shares the final...

06/08/2023

Oncology

Conference Coverage

Second-Line Use of CDK4/6 Inhibitors Plus Endocrine Therapy Superior to First-Line Use in Advanced Breast Cancer

06/05/2023

Janelle Bradley ;

First-line use of CDK4/6 inhibition plus endocrine therapy does not provide PFS benefit vs second-line use in patients with HR-positive, HER2-negative advanced breast cancer, according to results from the phase 3 SONIA trial.

First-line use of CDK4/6...

06/05/2023

Oncology

Conference Coverage

NATALEE Trial Results Support Ribociclib Plus Endocrine Therapy for HR-Positive, HER2-Negative Early Breast Cancer

06/05/2023

Janelle Bradley ;

Ribociclib added to endocrine therapy improves invasive disease-free survival in patients with HR-positive, HER2-negative early breast cancer according to findings from the NATALEE trial presented at the ASCO Annual Meeting.

Ribociclib added to endocrine...

06/05/2023

Oncology

Conference Coverage

Toripalimab Added to Nab-Paclitaxel Improves PFS in Metastatic or Recurrent Triple-Negative Breast Cancer

06/04/2023

Janelle Bradley ;

Findings from the phase 3 TORCHLIGHT trial show the addition of toripalimab to nab-paclitaxel significantly improves PFS in patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer.

Findings from the phase 3...

06/04/2023

Oncology

Recent News

News

Evaluating Inavolisib vs Alpelisib Plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

09/24/2024

Allison Casey ;

The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.

The ongoing INAVO121 trial is...

09/24/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

According to updated results...

05/31/2024

Oncology

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology